文献速递淋巴瘤

细胞周期蛋白依赖性激酶9是成人T细胞白血病/淋巴瘤的新型特异性分子靶点

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
PubMed 文献 · Blood · 2017-06-23

本研究评估选择性CDK9/P-TEFb抑制剂BAY 1143572在成人T细胞白血病/淋巴瘤(ATL)中的治疗潜力。BAY 1143572抑制CDK9及RNAPII CTD丝氨酸2磷酸化,降低c-Myc和Mcl-1水平,抑制ATL来源或HTLV-1转化细胞系及原代ATL细胞生长并诱导凋亡;在NOG小鼠ATL模型中,BAY 1143572治疗组较未治疗组显著减少肝脏和骨髓ATL细胞浸润、降低血清人可溶性白介素-2受体水平并显著延长生存期。

要点

  • BAY 1143572抑制CDK9/P-TEFb,降低ATL细胞c-Myc和Mcl-1水平,抑制生长并诱导凋亡。
  • BAY 1143572对ATL来源或HTLV-1转化细胞系、原代ATL细胞及健康志愿者CD4+细胞的中位抑制浓度分别为0.535、0.30和0.36 μM。
  • NOG小鼠ATL模型中,BAY 1143572(每日一次12.5 mg/kg口服)较未治疗组显著减少肝脏和骨髓ATL细胞浸润、降低血清人可溶性白介素-2受体水平并显著延长生存期。

核心结论

  • BAY 1143572作为新型CDK9/P-TEFb抑制剂,在ATL临床前模型中显示出作为新型治疗药物的强潜力。

研究设计与样本

  • 体外研究评估BAY 1143572对ATL来源或HTLV-1转化细胞系(n=8)、原代ATL细胞(n=11)及健康志愿者CD4+细胞(n=5)的作用。
  • 体内研究使用NOG小鼠接受一名ATL患者的肿瘤细胞,比较BAY 1143572治疗(每日一次12.5 mg/kg口服)与未治疗组。

主要发现

  • BAY 1143572抑制CDK9及RNAPII CTD丝氨酸2磷酸化,降低ATL来源或HTLV-1转化细胞系和原代ATL细胞中c-Myc和Mcl-1水平,导致生长抑制和凋亡。
  • BAY 1143572对ATL来源或HTLV-1转化细胞系(n=8)、原代ATL细胞(n=11)和健康志愿者CD4+细胞(n=5)的中位抑制浓度分别为0.535、0.30和0.36 μM。
  • BAY 1143572治疗的ATL荷瘤小鼠(每日一次12.5 mg/kg口服)较未治疗小鼠(两组n=8)肝脏和骨髓ATL细胞浸润显著减少,血清人可溶性白介素-2受体水平显著降低。
  • BAY 1143572治疗的ATL荷瘤小鼠较未治疗ATL荷瘤小鼠(两组n=7)生存期显著延长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cyclin-dependent kinase 9 (CDK9), a subunit of the positive transcription elongation factor b (P-TEFb) complex, regulates gene transcription elongation by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNAPII). The deregulation of CDK9/P-TEFb has important implications for many cancer types. BAY 1143572 is a novel and highly selective CDK9/P-TEFb inhibitor currently being investigated in phase 1 studies. We evaluated the therapeutic potential of BAY 1143572 in adult T-cell leukemia/lymphoma (ATL). As a result of CDK9 inhibition and subsequent inhibition of phosphorylation at serine 2 of the RNAPII CTD, BAY 1143572 decreased c-Myc and Mcl-1 levels in ATL-derived or human T-cell lymphotropic virus type-1 (HTLV-1)-transformed lines and primary ATL cells tested, leading to their growth inhibition and apoptosis. Median inhibitory concentrations for BAY 1143572 in ATL-derived or HTLV-1-transformed lines (n = 8), primary ATL cells (n = 11), and CD4+ cells from healthy volunteers (n = 5) were 0.535, 0.30, and 0.36 μM, respectively. Next, NOG mice were used as recipients of tumor cells from an ATL patient. BAY 1143572-treated ATL-bearing mice (once daily 12.5 mg/kg oral application) demonstrated significantly decreased ATL cell infiltration of the liver and bone marrow, as well as decreased human soluble interleukin-2 receptor levels in serum (reflecting the ATL tumor burden), compared with untreated mice (n = 8 for both). BAY 1143572-treated ATL-bearing mice demonstrated significantly prolonged survival compared with untreated ATL-bearing mice (n = 7 for both). Collectively, this study indicates that BAY 1143572 showed strong potential as a novel treatment of ATL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Narita T, Ishida T, Ito A, et al. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. Blood. 2017. PMID: 28646117. doi:10.1182/blood-2016-09-741983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。